Primary biliary cholangitis Trials in Coronado, United States
Conditions / Primary biliary cholangitis / Coronado, United States
Primary biliary cholangitis is a medical condition with active clinical research programs worldwide.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06247735 | Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment. | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06447168 | A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment | RECRUITING | — |
| NCT03742973 | A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA | TERMINATED | PHASE2 |
| NCT03394924 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis | COMPLETED | PHASE2 |
| NCT05104853 | Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis | COMPLETED | PHASE1/PHASE2 |
| NCT05050136 | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | RECRUITING | PHASE2 |
| NCT05239468 | Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC | COMPLETED | PHASE2 |
| NCT06525311 | A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis. | COMPLETED | PHASE1 |
| NCT06383403 | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. | ACTIVE_NOT_RECRUITING | — |
| NCT06488911 | To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate | TERMINATED | PHASE3 |